Jane Street’s Karyopharm Therapeutics KPTI Stock Holding History

Jane Street’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$80.2K	Sell	14,400 -21,300	-60%	-$162K	﹤0.01%	10743
2025 Q4	$263K	Buy	+35,700	New	+$218K	﹤0.01%	9127
2023 Q3	–	Sell	-1,093	Closed	-$29.4K	–	9036
2023 Q2	$29.4K	Buy	1,093 +333	+44%	+$14.3K	﹤0.01%	8313
2023 Q1	$44.3K	Buy	+760	New	+$37.5K	﹤0.01%	8482
2022 Q4	–	Sell	-1,840	Closed	-$151K	–	9656
2022 Q3	$151K	Sell	1,840 -1,140	-38%	-$85.2K	﹤0.01%	8394
2022 Q2	$202K	Sell	2,980 -3,347	-53%	-$307K	﹤0.01%	8177
2022 Q1	$699K	Buy	6,327 +4,974	+368%	+$620K	﹤0.01%	6851
2021 Q4	$131K	Sell	1,353 -140	-9%	-$14K	﹤0.01%	9093
2021 Q3	$130K	Buy	1,493 +66	+5%	+$6.85K	﹤0.01%	9148
2021 Q2	$221K	Sell	1,427 -1,500	-51%	-$218K	﹤0.01%	8665
2021 Q1	$462K	Sell	2,927 -640	-18%	-$135K	﹤0.01%	6945
2020 Q4	$828K	Buy	3,567 +1,280	+56%	+$297K	﹤0.01%	4977
2020 Q3	$501K	Sell	2,287 -1,033	-31%	-$253K	﹤0.01%	5152
2020 Q2	$943K	Buy	+3,320	New	+$982K	﹤0.01%	4146

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Jane Street's KPTI Position: Q1 2026 in Review

Jane Street increased its Karyopharm Therapeutics (KPTI) stake by 198% in Q1 2026, buying an estimated $536K and bringing the position to 105,901 shares worth $590K. The position accounts for ﹤0.01% of the portfolio, ranked #7664.

Jane Street first reported a position in KPTI in Q2 2014 and has held it in 23 quarters since. The position peaked at $3.07M in Q1 2022. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Jane Street held 105,901 shares of Karyopharm Therapeutics worth $590K as of Q1 2026.
Jane Street bought 70,368 Karyopharm Therapeutics shares in Q1 2026, an estimated $536K.
Karyopharm Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7664 holding.
Jane Street first reported a position in Karyopharm Therapeutics in Q2 2014 and has held it in 23 quarters since.
Jane Street's Karyopharm Therapeutics position peaked at $3.07M in Q1 2022.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.